nach oben

Journal of Gastrointestinal Surgery

Erschienen in:

01.05.2011 | 2011 SSAT Annual Meeting

An Evidence-Based Review of the Surgical Treatment of Gastric Adenocarcinoma

verfasst von: Ugwuji N. Maduekwe, Sam S. Yoon

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

The management of gastric adenocarcinoma continues to evolve. Chemotherapy is being increasingly used in both the neoadjuvant and adjuvant setting. Surgical resection of the stomach and regional lymph nodes remains the mainstay of potentially curative therapy, but significant regional differences persist in the surgical management. This review provides an update on the current literature regarding the preoperative evaluation and staging, extent of gastric resection, extent of lymph node resection, and adjuvant therapy for patients with gastric adenocarcinoma.

Cancer. World Health Organization fact sheet No 297 [serial online] 2009. http://www.who.int/mediacentre/factsheets/fs297/en/index.html

Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007;14:78–85.PubMed

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.PubMedCrossRef

Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354–362.PubMed

Pisters PWT, Kelsen DP, Teper JE. Cancer of the stomach. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 9th edition. Philadelphia: Lippincott Williams & Wilkins; 2008;1741–1794.

Pandalai PK, Yoon SS. Hereditary diffuse gastric cancer. In: Chung DC, Haber DA, eds. Principals of Clinical Cancer Genetics. New York: Springer; 2010;97–107.CrossRef

Gotoda T, Yanagisawa A, Sasako M et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000;3:219–225.PubMedCrossRef

Suzuki H, Gotoda T, Sasako M, Saito D. Detection of early gastric cancer: misunderstanding the role of mass screening. Gastric Cancer 2006;9:315–319.PubMedCrossRef

Ahn HS, Lee HJ, Yoo MW et al. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2010.

10.

Lauren P. THE two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.PubMed

11.

Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. J Surg Oncol 2005;90:114–133.PubMedCrossRef

12.

Kunisaki C, Shimada H, Nomura M, Matsuda G, Otsuka Y, Akiyama H. Therapeutic strategy for signet ring cell carcinoma of the stomach. Br J Surg 2004;91:1319–1324.PubMedCrossRef

13.

Park JM, Jang YJ, Kim JH et al. Gastric cancer histology: clinicopathologic characteristics and prognostic value. J Surg Oncol 2008;98:520–525.PubMedCrossRef

14.

Aranha GV, Georgen R. Gastric linitis plastica is not a surgical disease. Surgery 1989;106:758–762.PubMed

15.

Kodera Y, Ito S, Mochizuki Y, et al. The number of metastatic lymph nodes is a significant risk factor for bone metastasis and poor outcome after surgery for linitis plastica-type gastric carcinoma. World J Surg 2008;32:2015–2020.PubMedCrossRef

16.

Puli SR, BatapatiKrishna RJ, Bechtold ML, Antillon MR, Ibdah JA. How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review. World J Gastroenterol 2008;14:4011–4019.PubMedCrossRef

17.

Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 2009;35:449–455.PubMed

18.

Lim JS, Yun MJ, Kim MJ et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006;26:143–156.PubMedCrossRef

19.

Power DG, Schattner MA, Gerdes H et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg 2009;208:173–178.PubMedCrossRef

20.

Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 2009;16:3227–3236.PubMedCrossRef

21.

Lorenzen S, Panzram B, Rosenberg R, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol 2010;17:2733–2739.PubMedCrossRef

22.

AJCC Cancer Staging Manual. 6th edition. New York, NY: Springer; 2002.

23.

AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.

24.

Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989;209(2):162–166.

25.

Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastointestinal Tumor Study Group. Ann Surg 1999;230(2):170–178.

26.

Ishikawa M, Kitayama J, Kaizaki S, et al. Prospective randomized trial comparing Billroth I and Roux-en-Y procedures after distal gastrectomy for gastric carcinoma. World J Surg 2005;29:1415–1420.PubMedCrossRef

27.

Montesani C, D'Amato A, Santella S, et al. Billroth I versus Billroth II versus Roux-en-Y after subtotal gastrectomy. Prospective [correction of prespective] randomized study. Hepatogastroenterology 2002;49:1469–1473.PubMed

28.

Viste A, Haugstvedt T, Eide GE, Soriede O. Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988;207(1):7–13.

29.

An JY, Youn HG, Choi MG, Noh JH, Sohn TS, Kim S. The difficult choice between total and proximal gastrectomy in proximal early gastric cancer. Am J Surg 2008;196:587–591.PubMedCrossRef

30.

Harrison LE, Karpeh MS, Brennan MF. Total gastrectomy is not necessary for proximal gastric cancer. Surgery 1998;123:127–130.PubMedCrossRef

31.

Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Long-term outcome after proximal gastrectomy with jejunal interposition for suspected early cancer in the upper third of the stomach. Br J Surg 2010;97:558–562.PubMedCrossRef

32.

Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia of subcardia: a randomised controlled trial. Lancet Oncol 2006;7(8):644–651.

33.

Fein M, Fuchs KH, Thalheimer A, Freys SM, Heimbucher J, Thiede A. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg 2008;247:759–765.PubMedCrossRef

34.

Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery. Jpn J Surg 1973;3:61.CrossRef

35.

Nishi M, Omori Y, Miwa K. Japanese Classification of Gastric Carcinoma. Kanehara & Co., Ltd; 1995.

36.

Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition—response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 2001;4:1–8.CrossRef

37.

Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418–425.PubMedCrossRef

38.

Kampschoer GH, Maruyama K, van de Velde CJ, Sasako M, Kinoshita T, Okabayashi K. Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg 1989;76:905–908.PubMedCrossRef

39.

Siewert JR, Kelsen D, Hoelscher AH. Gastric cancer diagnosis and treatment—an interactive training program. Berlin: Springer Electronic Media; 2000.

40.

Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer 1998;1:125–133.PubMedCrossRef

41.

Bollschweiler E, Boettcher K, Hoelscher AH et al. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg 1992;79:156–160.PubMedCrossRef

42.

Guadagni S, de Manzoni G, Catarci M et al. Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. World J Surg 2000;24:1550–1558.PubMedCrossRef

43.

Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006;107:2143–2151.PubMedCrossRef

44.

Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002;94:2862–2866.PubMedCrossRef

45.

Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005;23:7114–7124.PubMedCrossRef

46.

Estes NC, Macdonald JS, Touijer K, Benedetti J, Jacobson J. Inadequate documentation and resection for gastric cancer in the United States: a preliminary report. Am Surg 1998;64:680–685.PubMed

47.

Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1–11.PubMed

48.

Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.PubMedCrossRef

49.

D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808–816.PubMedCrossRef

50.

Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810–1820.PubMedCrossRef

51.

Sasako M, Sano T, Katai H, et al. Radical surgery. In: Sugimura T, Sasako M. Gastric Cancer. Oxford: Oxford University Press, 1997:223–249.

52.

Lee HK, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg 2001;88:1408–1412.PubMedCrossRef

53.

Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449–461.PubMedCrossRef

54.

Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg 2000;232:362–371.PubMedCrossRef

55.

Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995–999.PubMedCrossRef

56.

Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745–748.PubMedCrossRef

57.

Jansen EP, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005;23:4509–4517.PubMedCrossRef

58.

Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995;19:532–536.PubMedCrossRef

59.

Uyama I, Ogiwara H, Takahara T et al. Spleen- and pancreas-preserving total gastrectomy with superextended lymphadenectomy including dissection of the para-aortic lymph nodes for gastric cancer. J Surg Oncol 1996;63:268–270.PubMedCrossRef

60.

Biffi R, Chiappa A, Luca F et al. Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: low morbidity and mortality rates in a single center series of 250 patients. J Surg Oncol 2006;93:394–400.PubMedCrossRef

61.

Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309–315.PubMedCrossRef

62.

Roggin KK, Posner MC. D3 or not D3… that is not the question. Lancet Oncol 2006;7:279–280.PubMedCrossRef

63.

Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F. Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 1998;16:1490–1493.PubMed

64.

Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30:303–308.PubMed

65.

Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010;97:643–649.PubMedCrossRef

66.

Kitamura K, Nishida S, Ichikawa D et al. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Br J Surg 1999;86:119–122.PubMedCrossRef

67.

Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401–407.PubMedCrossRef

68.

Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559–563.PubMedCrossRef

69.

Sano T, Yamamoto S, Sasako M. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol 2002;32:363–364.PubMedCrossRef

70.

Sano T, Sasako M, Yamamoto S et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767–2773.PubMedCrossRef

71.

Sasako M, Sano S, Yamanoto A et al. Randomized phase III trial of standard D2 versus D2 + para-aortic lymph node (PAN) dissection (D) for clinically M0 advanced gastric cancer: JCOG9501. Proceedings of the American Society of Clinical Oncology 2006; Abstract LBA4015.

72.

Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005;92:1099–1102.PubMedCrossRef

73.

Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128–1137.PubMedCrossRef

74.

Smith DL, Elting LS, Learn PA, Raut CP, Mansfield PF. Factors influencing the volume-outcome relationship in gastrectomies: a population-based study. Ann Surg Oncol 2007;14:1846–1852.PubMedCrossRef

75.

Smith JK, McPhee JT, Hill JS et al. National outcomes after gastric resection for neoplasm. Arch Surg 2007;142:387–393.PubMedCrossRef

76.

Marcus SG, Cohen D, Lin K et al. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg 2003;7:1015–1022.PubMedCrossRef

77.

Lee JH, Ryu KW, Lee JH et al. Learning curve for total gastrectomy with D2 lymph node dissection: cumulative sum analysis for qualified surgery. Ann Surg Oncol 2006;13:1175–1181.PubMedCrossRef

78.

Luglio G, Nelson H. Laparoscopy for colon cancer: state of the art. Surg Oncol Clin N Am 2010;19:777–791.PubMedCrossRef

79.

Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994;4:146–148.PubMed

80.

Kitano S, Shiraishi N, Kakisako K, Yasuda K, Inomata M, Adachi Y. Laparoscopy-assisted Billroth-I gastrectomy (LADG) for cancer: our 10 years' experience. Surg Laparosc Endosc Percutan Tech 2002;12:204–207.PubMedCrossRef

81.

Huscher CG, Mingoli A, Sgarzini G et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg 2005;241:232–237.PubMedCrossRef

82.

Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc 2005;19:168–173.PubMedCrossRef

83.

Kitano S, Shiraishi N, Fujii K, Yasuda K, Inomata M, Adachi Y. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 2002;131:S306–S311.PubMedCrossRef

84.

Hayashi H, Ochiai T, Shimada H, Gunji Y. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 2005;19:1172–1176.PubMedCrossRef

85.

Kim HH, Hyung WJ, Cho GS et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251:417–420.PubMedCrossRef

86.

Kodera Y, Fujiwara M, Ohashi N et al. Laparoscopic surgery for gastric cancer: a collective review with meta-analysis of randomized trials. J Am Coll Surg 2010;211:677–686.PubMedCrossRef

87.

Kitano S, Shiraishi N, Uyama I, Sugihara K, Tanigawa N. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg 2007;245:68–72.PubMedCrossRef

88.

Lee SW, Nomura E, Bouras G, Tokuhara T, Tsunemi S, Tanigawa N. Long-term oncologic outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive resections. J Am Coll Surg 2010;211:33–40.PubMedCrossRef

89.

Strong VE, Devaud N, Karpeh M. The role of laparoscopy for gastric surgery in the West. Gastric Cancer 2009;12:127–131.PubMedCrossRef

90.

Strong VE, Devaud N, Allen PJ, Gonen M, Brennan MF, Coit D. Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. Ann Surg Oncol 2009;16:1507–1513.PubMedCrossRef

91.

Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 2005;8:78–85.PubMedCrossRef

92.

Kim S, Lim DH, Lee J et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279–1285.PubMedCrossRef

93.

Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.PubMedCrossRef

94.

Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:34–36.PubMed

95.

NCCN Clinical Practice Guidelines in Oncology—v.2.2020: Gastric Cancer. 1-1-2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

Titel: An Evidence-Based Review of the Surgical Treatment of Gastric Adenocarcinoma
verfasst von: Ugwuji N. Maduekwe
Sam S. Yoon
Publikationsdatum: 01.05.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Gastrointestinal Surgery / Ausgabe 5/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-011-1477-y

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Barrett’s Esophagus: A Review of the Literature

Alternating Treatment with S-1 Plus Low-Dose Cisplatin and S-1 Alone for Advanced Gastric Cancer

Bypass Surgery Versus Intentionally Incomplete Resection in Palliation of Pancreatic Cancer: Is Resection the Lesser Evil?

Achalasia and Other Esophageal Motility Disorders

Management of Esophageal Perforation and Anastomotic Leak by Transluminal Drainage

Effect of Antecolic or Retrocolic Reconstruction of the Gastro/Duodenojejunostomy on Delayed Gastric Emptying After Pancreaticoduodenectomy: A Randomized Controlled Trial

Update Chirurgie